<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901288</url>
  </required_header>
  <id_info>
    <org_study_id>2015ZX10003001</org_study_id>
    <nct_id>NCT02901288</nct_id>
  </id_info>
  <brief_title>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</brief_title>
  <official_title>Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hubei Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Tuberculosis Control of Guangdong Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Institute For Tuberculosis Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Center for Disease Prevention and Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Institute for Tuberculosis Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Shenyang Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changchun Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Clinical Center of Chengdu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiyuan Fourth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth People's Hospital of Nantong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Tuberculosis Prevention and Treatment Hospital of Shanxi Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Research Institute for Tuberculosis Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease Prevention Hospital in Heilongjiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Zhenjiang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heilongjiang Province center for tuberculosis Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Haihe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Infectious Disease Hospital of Wangkai Zaozhuang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Kunming City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaifeng Pulmonary Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Infectious Hospital of Hebi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pulmonary Hospital of Lanzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth People's Hospital of Ningxia Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 4th People's Hospital of Qinghai Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth People's Hospital of Suzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Infectious Disease Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tuberculosis Hospital in Jilin Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth People's Hospital of Nanyang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan medical treatment center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of two shortened regimens for
      newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World
      Health Organization recommended standard 6-month regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Design: The study is a multi-center, randomized,controlled non-inferiority trial.

        2. Population: patients with newly diagnosed drug-susceptible pulmonary TB who fulfill the
           inclusion and exclusion criteria.

        3. Investigational regimens:

           Experimental group 1 regimen consists of levofloxacin, isoniazid , rifampicin,ethambutol
           and pyrazinamide for 4.5 months.

           Experimental group 2 regimen consists of isoniazid, rifampicin, ethambutol and
           pyrazinamide for 4.5 months.

           The control group is WHO recommended regimen conmposed of isoniazid , rifampicin,
           ethambutol and pyrazinamide for 2 months, followed by isoniazid , rifampicin for 4
           months.

           Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once
           daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg(less than
           50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than
           50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than
           50kg,given once daily) or 800mg(more than 50kg,once daily)..

        4. Trial objectives: to evaluate that shortened regimens is not inferior to standard
           treatment in terms of efficacy and safety for new smear positive pulmonary TB patients.

        5. Primary and Secondary outcome measures:

           The primary efficacy outcome measures include (a)the percentage of participants with TB
           recurrence/relapse by 24 months after the end of treatment;(b) percentage of
           participants with treatment failure at either 4.5 months or 6 months after
           randomization. (a) Time to sputum smear or culture conversion within intensive phase.(b)
           Sputum smear conversion proportion at the treatment completion. (c) Number of adverse
           drug reaction occurring during treatment or follow-up period. (d) Radiological
           manifestation change of TB lesion or cavity.(e) Patients adherence rate.

        6. Sample Size:

           Approximately 3900 participants will be enrolled and randomized with 1:1:1 ratio into
           either Experimental group1, Experimental group2 or control group.

        7. Blinding:

           The study is an open-label study.

        8. Assessment and follow-up:

      All patients will be followed by to 2 years after completion of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of participants with TB recurrence/relapse by 24 months after the end of treatment.</measure>
    <time_frame>24 months after treatment completion for all 3 groups</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with treatment failure at either 4.5 months or 6 months after randomization.</measure>
    <time_frame>4.5 months after randomization for experimental group1 and 2; 6 months after randomization for control group</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment adverse reactions occuring</measure>
    <time_frame>An average of 6 months for control group and 4.5 months for experimental group1 and 2 during treatment and 24 months after treatment completion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sputum smear or culture conversion within intensive phase .</measure>
    <time_frame>An avergae of 2-3 months after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum smear or culture conversion proportion at the treatment completion.</measure>
    <time_frame>An average of 6 months for control group while 4.5 months for experimental group 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological manifestation change of TB lesion or cavity.</measure>
    <time_frame>An average of 6 months during treatment and 24 months after treatment completion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patiens adherence rate</measure>
    <time_frame>An average of 6 months during treatment and 24 months after treatment completion.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3900</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.
Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control regimen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).
Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.</description>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_label>experimental group2</arm_group_label>
    <arm_group_label>Control regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin is a widely used anti-tuberculosis medication.</description>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_label>experimental group2</arm_group_label>
    <arm_group_label>Control regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.</description>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_label>experimental group2</arm_group_label>
    <arm_group_label>Control regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.</description>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_label>experimental group2</arm_group_label>
    <arm_group_label>Control regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.</description>
    <arm_group_label>experimental group1</arm_group_label>
    <other_name>Cravit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is willing and able to give informed consent to participate in the trial treatment and
             follow-up (signed or witnessed consent if the patient is illiterate).

          2. Is aged 18-65 years.

          3. Has twice positive acid-fast bacilli(AFB) sputum smear or positive sputum culture
             result, along with chest x-ray imaging consistent with active pulmonary tuberculosis.

          4. Newly diagnosed cases receiving anti-TB treatment for less than one month

          5. Urine Human Chorionic Gonadotropin(U-HCG) negative and must agree to use effective
             contraception during the trial period.

          6. Has Alanine aminotransferase（ALT）and Total bilirubin（TBil） less than 2 times the upper
             limit of normal ; has Creatinine clearance rate （CrCI） more than 30ml/min; has
             Hemoglobin more than 7.0g/dL; has Platelet（PLT）more than 50 x10^9/L before study
             entry.

        Exclusion Criteria:

          1. Concomitant severe cardiovascular, liver, kidney, nervous system, hematopoietic system
             and other diseases, or concomitant neoplastic diseases. Or extensive lesion with
             respiratory insufficiency.

          2. Uncontrolled diabetes mellitus.

          3. Concomitant mental disorders.

          4. Is HIV positive.

          5. Is critically ill, and in the judgment of the investigator, not fit for the study or
             unlikely to complete the full course of study.

          6. Is known to be pregnant or breast-feeding.

          7. Is unable or unwilling to comply with the treatment, assessment, or follow-up
             schedule.

          8. Is taking any medications contraindicated with the medicines in any trial regimen of
             the study.

          9. Has a known allergy to any drug of treatment regimens.

         10. Is currently taking part in another trial.

         11. Has a QTc interval more than 480ms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenjie Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenjie Tang, MD</last_name>
    <email>tangsj1106@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gang Liu</last_name>
      <phone>13955168886</phone>
      <email>liu802208@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Research Institute for Tuberculosis Control</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaoxin he</last_name>
      <phone>13718716778</phone>
      <email>hexiaoxinbj@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital,Capital Meical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mengqiu Gao</last_name>
      <phone>13611009420</phone>
      <email>gaomqwdm@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Infectious Disease Medical Center</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>500106</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaofeng yan</last_name>
      <phone>15922784944</phone>
      <email>2429918342@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Hospital of Lanzhou</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Ma</last_name>
      <phone>13919319518</phone>
      <email>lfmjj50@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Tuberculosis Control of Guangdong Province</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huizhong wu</last_name>
      <phone>13798123288</phone>
      <email>1627639699@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Center for Disease Prevention and Control</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shuhai Huang</last_name>
      <phone>13877102829</phone>
      <email>shuhaihuang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HeBei Province Center for Disease Prevention and Control</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>haifeng chen</last_name>
      <phone>13503311328</phone>
      <email>chenhaifeng2071@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Prevention Hospital in Heilongjiang Province</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jintao tang</last_name>
      <phone>13766987870</phone>
      <email>liuyuqin_ssy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Province center for tuberculosis Control and Prevention</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanling Yu</last_name>
      <phone>18645092935</phone>
      <email>hljlfb@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Chest Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lianzhi Wang</last_name>
      <phone>13836176215</phone>
      <email>1186433640@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Infectious Hospital of Hebi</name>
      <address>
        <city>Hebi</city>
        <state>Henan</state>
        <zip>458000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lin zhang</last_name>
      <phone>13783022531</phone>
      <email>923657539@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaifeng Pulmonary Disease Hospital</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <zip>475000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhenya Ma</last_name>
      <phone>13937886599</phone>
      <email>861852536@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sixth People's Hospital of Nanyang City</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shulin zhai</last_name>
      <phone>13598220698</phone>
      <email>106273621@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xianxiang</city>
        <state>Henan</state>
        <zip>453100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiuqin Cui</last_name>
      <phone>15837315900</phone>
      <email>cuixiuqin4402973@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan medical treatment center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ming wei</last_name>
      <phone>13667221289</phone>
      <email>1508257434@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Institute For Tuberculosis Control</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>peng peng</last_name>
      <phone>13397192727</phone>
      <email>pengpengwg@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Institute For Tuberculosis Control</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yisheng Huang</last_name>
      <phone>139-7516-9056</phone>
      <email>1756325210@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Nantong</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying Yuan</last_name>
      <phone>13906293240</phone>
      <email>515020737@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>meiying Wu</last_name>
      <phone>13906133614</phone>
      <email>wu-my@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Zenjiang</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hongqiu Pan</last_name>
      <phone>13951286001</phone>
      <email>1622728518@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changchun Infectious Disease Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jian Zhang</last_name>
      <phone>13944141394</phone>
      <email>jianzhang20080808@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tuberculosis Hospital in Jilin Province</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <zip>132000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>peng Sun</last_name>
      <phone>13630567999</phone>
      <email>763515780@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Shenyang Chest Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Jilin</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>juan Zhang</last_name>
      <phone>18840000208</phone>
      <email>tb10ywk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Ningxia Autonomous Region</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guoren Ma</last_name>
      <phone>18909508998</phone>
      <email>zhyl114@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 4th People's Hospital of Qinghai Province</name>
      <address>
        <city>Xining Shi</city>
        <state>Qinghai</state>
        <zip>810000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenyuan Zhang</last_name>
      <phone>13519707409</phone>
      <email>13519707409@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Infectious Disease Hospital of Wangkai Zaozhuang</name>
      <address>
        <city>Tengzhou</city>
        <state>Shandong</state>
        <zip>277500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanyou chu</last_name>
      <phone>13626329377</phone>
      <email>lw978@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lin Fan</last_name>
      <phone>13918569516</phone>
      <email>fanlinsj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiyuan Fourth People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Gao</last_name>
      <phone>13613456715</phone>
      <email>398799102@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tuberculosis Prevention and Treatment Hospital of Shanxi Province</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qianhong wu</last_name>
      <phone>13891927416</phone>
      <email>2271515862@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Public Health Clinical Center of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guihui Wu</last_name>
      <phone>13056668540</phone>
      <email>wghwgh2584@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Haihe Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zaoxian Mei</last_name>
      <phone>18920180092</phone>
      <email>1796135865@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin centers for Disease Control and Prevention</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanyong fu</last_name>
      <phone>13312129913</phone>
      <email>fuyanyong@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ertai a</last_name>
      <phone>18999853468</phone>
      <email>xkyyaertai@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Kunming City</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mingwu Li</last_name>
      <phone>13888428168</phone>
      <email>wanrong123@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Tang Shenjie</investigator_full_name>
    <investigator_title>Director, TB Department</investigator_title>
  </responsible_party>
  <keyword>pulmonary tuberculosis</keyword>
  <keyword>shortened regimen</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

